Ranbaxy Laboratories Ltd (RANB.BO)

RANB.BO on Bombay Stock Exchange

617.60INR
21 Nov 2014
Price Change (% chg)

Rs-6.10 (-0.98%)
Prev Close
Rs623.70
Open
Rs617.50
Day's High
Rs624.95
Day's Low
Rs611.25
Volume
110,613
Avg. Vol
164,150
52-wk High
Rs697.50
52-wk Low
Rs306.05

RANB.BO

Chart for RANB.BO

About

Ranbaxy Laboratories Limited is an integrated international pharmaceuticals company. The Company is engaged in the marketing, production and distribution of pharmaceutical products. The Company’s business activity falls within a single primary business segment viz. Pharmaceutical. The Company has ground operations in over 40... (more)

Overall

Beta: 0.59
Market Cap (Mil.): Rs264,700.00
Shares Outstanding (Mil.): 424.57
Dividend: --
Yield (%): --

Financials

  RANB.BO Industry Sector
P/E (TTM): 463.18 38.05 39.20
EPS (TTM): 1.35 -- --
ROI: -- 17.86 17.16
ROE: -- 18.61 18.09
Search Stocks

U.S. court denies Ranbaxy's bid to block launch of rival generics

REUTERS - A U.S. court has denied a request by drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche's antiviral, a court filing showed.

20 Nov 2014

U.S. court overturns bid by India's Ranbaxy to block launch of rival generic drugs

Nov 20 - A U.S. court has denied a request by Indian drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche's antiviral Valcyte, a court filing showed.

20 Nov 2014

Ranbaxy sues FDA over revoking approvals for Nexium, Valcyte copies

MUMBAI - Ranbaxy Laboratories Ltd has sued the U.S. Food and Drug Administration (FDA) for revoking approvals granted to the Indian firm to launch copies of two drugs including AstraZeneca Plc's heartburn pill Nexium, court documents showed.

18 Nov 2014

Ranbaxy sues FDA over revoking approvals for Nexium, Valcyte copies

MUMBAI - Ranbaxy Laboratories Ltd has sued the U.S. Food and Drug Administration (FDA) for revoking approvals granted to the Indian firm to launch copies of two drugs including AstraZeneca Plc's heartburn pill Nexium, court documents showed.

18 Nov 2014

UPDATE 1-Ranbaxy sues FDA over revoking approvals for Nexium, Valcyte copies

* Ranbaxy alleges FDA's move violated constitutional rights

18 Nov 2014

Ranbaxy sues FDA over revoking approvals for Nexium, Valcyte copies

MUMBAI, Nov 18 - Ranbaxy Laboratories Ltd has sued the U.S. Food and Drug Administration (FDA) for revoking approvals granted to the Indian firm to launch copies of two drugs including AstraZeneca Plc's heartburn pill Nexium, court documents showed.

18 Nov 2014

UPDATE 2-India's Sun Pharma Q2 profit up 15 pct; Cipla down on slowing exports

* Sun Q2 profit up 15 pct, roughly in line with street estimates

13 Nov 2014

U.S. pulls approval for Ranbaxy copies of AstraZeneca and Roche drugs

MUMBAI - The U.S. Food and Drug Administration (FDA) has revoked a tentative approval for Ranbaxy Laboratories Ltd to make a cheap copy of AstraZeneca Plc's heartburn drug Nexium, after its Indian plants were banned over quality control issues.

06 Nov 2014

U.S. pulls approval for Ranbaxy copies of AstraZeneca and Roche drugs

MUMBAI - The U.S. Food and Drug Administration (FDA) has revoked a tentative approval for India's Ranbaxy Laboratories Ltd to make a cheap copy of AstraZeneca Plc's heartburn drug Nexium, after its Indian plants were banned over quality control issues.

06 Nov 2014

UPDATE 2-U.S. pulls approval for Ranbaxy copies of AstraZeneca and Roche drugs

* Ranbaxy says FDA revoked approval for copies of Nexium, Valcyte

06 Nov 2014

Earnings vs. Estimates

Search Stocks